The short version of Aseptic technique fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-28. Anything still debated is marked as such rather than presented as settled.
After reconstitution, a peptide solution is typically stored under conditions that limit degradation. Cool temperatures slow hydrolysis and oxidation, while freezing can preserve samples for longer periods. Repeated freeze-thaw cycles may promote aggregation or precipitation, so aliquoting before freezing is a common laboratory practice. The optimal storage temperature depends on the peptide sequence, buffer composition, and expected duration. Solutions containing oxidizable residues may benefit from inert gas overlays or antioxidants, though compatibility with the specific peptide must be considered.
Aseptic technique matters because aqueous peptide solutions can support microbial growth. Sterile solvents, clean workspaces, and sterile filtration can reduce contamination. The choice of filter material and pore size must avoid peptide loss through adsorption, especially for hydrophobic or low-concentration samples. Visual inspection for particles, turbidity, or color change provides a simple initial check, but it cannot confirm identity or purity. Analytical methods such as reversed-phase high-performance liquid chromatography and mass spectrometry are used to verify composition and detect degradation products.
Aseptic technique matters when the solution will contact cells or biological reagents. Working in a clean environment, using sterile liquids and containers, and minimizing open-vial time reduce the chance of microbial contamination. Filtration through a sterile filter can remove particles and microorganisms, but some filters adsorb peptides and some peptides are retained by certain membrane materials. Compatibility between the peptide, solvent, and filter should be checked when recovery is critical.
Quality verification after reconstitution may include visual inspection, pH measurement, and chromatographic analysis. Reverse-phase high-performance liquid chromatography can reveal degradation peaks, while mass spectrometry can confirm molecular identity. Concentration may be estimated from the weighed peptide mass or determined by amino acid analysis, UV absorbance, or quantitative chromatography. Documentation of solvent, volume, date, and storage conditions supports traceability and reproducibility. Records also help identify when a solution was prepared and whether it has exceeded an established in-house shelf life.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature (lyophilized) | -20 °C or lower | Desiccant and sealed container limit moisture |
| Typical storage temperature (reconstituted) | 2-8 °C short term; frozen for longer | Freeze-thaw cycles may damage peptide |
| Appearance of solution | Clear to slightly opalescent | Turbidity or particles suggest aggregation or contamination |
| Identity method | Mass spectrometry | Confirms molecular mass and detects modifications |
| Purity method | Reversed-phase HPLC | Separates peptide from related impurities |
After reconstitution, peptide solutions are generally less stable than lyophilized powders, and hydrolysis, oxidation, deamidation, and aggregation can occur in solution. Stability depends on peptide sequence, concentration, pH, buffer composition, temperature, light exposure, and dissolved oxygen. Many research protocols store reconstituted solutions at 4 °C for short periods or at -20 °C or -80 °C for longer periods. Repeated freeze-thaw cycles can promote aggregation and loss of activity. The optimal storage condition is peptide-specific and often determined empirically rather than predicted from sequence alone.
Quality control after reconstitution often includes visual inspection for particulates, pH measurement, and concentration determination by ultraviolet absorbance at 280 nm when aromatic residues are present. Reverse-phase high-performance liquid chromatography can assess purity and reveal degradation peaks. Mass spectrometry confirms molecular identity and detects modifications such as oxidation or truncation. Size-exclusion chromatography can quantify aggregates and oligomers. These methods are established for many peptides but may require optimization for hydrophobic or chemically modified sequences.
Microbial contamination is a concern for aqueous peptide solutions, especially those without preservatives. Bacteriostatic water contains an antimicrobial preservative and is used in some laboratory settings, while sterile water lacks preservatives. Filtration through a sterile filter can reduce particulates and microbes, but some peptides adsorb to filter membranes. The effect of preservatives on peptide stability is peptide-dependent and not fully predictable. Documentation of lot number, solvent, date, and storage conditions supports traceability and reproducibility.
During reconstitution, solvent penetrates the dry cake and breaks intermolecular contacts that held the peptide in solid form. Dissolution occurs as individual peptide molecules become surrounded by solvent. Hydrophobic regions can associate with one another instead of dissolving, which may produce turbidity or aggregates. pH and ionic strength influence the charge state of ionizable groups and therefore solubility. Buffer salts can help maintain a stable pH, but they can also participate in interactions that affect the final solution.
The concentration of a reconstituted peptide is calculated from the mass of peptide powder and the volume of solvent added. This calculation assumes the powder contains only peptide, but many preparations include counterions, water, or salts. Analytical methods such as ultraviolet absorbance or amino acid analysis can estimate actual peptide content. The relationship between nominal and actual concentration is an area where measurements matter. Open questions remain about how aggregation changes the effective concentration in solution.
Peptide reconstitution is the process of dissolving a lyophilized peptide in a liquid to form a solution for later use. Lyophilization removes water under vacuum, leaving a dry powder or porous cake. Reconstitution reintroduces solvent so the peptide molecules return to a dissolved state. The solvent may be purified water, a buffer, or a mixture containing an organic co-solvent. The choice depends on the peptide sequence, its charge, and its hydrophobicity.
A suture is a type of fibrous joint that is only found in the skull (cranial suture). The bones are bound together by Sharpey's fibres. A tiny amount of movement is permitted at sutures, which contributes to the compliance and elasticity of the skull. These joints are synarthroses. It is normal for many of the bones of the skull to remain unfused at birth. The fusion of the skull's bones before birth is known as craniosynostosis. The term "fontanelle" is used to describe the resulting "soft spots". The relative positions of the bones continue to change during the life of the adult (though less rapidly), which can provide useful information in forensics and archaeology. In old age, cranial sutures may ossify (turn to bone) completely. The joints between the teeth and jaws (gomphoses) and the joint between the mandible and the cranium, the temporomandibular joint, form the only non-sutured joints in the skull.
A significant player in the process is transforming growth factor (TGFβ). This protein appears to be overproduced, and the fibroblast (possibly in response to other stimuli) also overexpresses the receptor for this mediator. An intracellular pathway (consisting of SMAD2/SMAD3, SMAD4, and the inhibitor SMAD7) is responsible for the secondary messenger system that induces transcription of the proteins and enzymes responsible for collagen deposition. Sp1 is a transcription factor most closely studied in this context. Apart from TGFβ, connective tissue growth factor (CTGF) has a possible role. Indeed, a common CTGF gene polymorphism is present at an increased level in systemic sclerosis. Damage to endothelium is an early abnormality in the development of scleroderma, and this, too, seems to be due to collagen accumulation by fibroblasts, although direct alterations by cytokines, platelet adhesion, and a type II hypersensitivity reaction similarly have been implicated. Increased endothelin and decreased vasodilation have been documented. Jimenez and Derk describe three theories about the development of scleroderma:
Molybdenum (42Mo) has seven isotopes in nature, with atomic masses of 92, 94-98, and 100. All are stable except 100Mo, which undergoes double beta decay with a half-life of 7.07×1018 years (the shortest known for this mode) to 100Ru. 92Mo and 98Mo are also energetically able to decay in this manner, to zirconium and ruthenium respectively; the others are theoretically stable. There are also a total of 32 synthetic isotopes known, and at least 13 metastable nuclear isomers, ranging in atomic mass from 81 to 119. The isotopes with mass 93 or lower decay by electron capture or positron emission to niobium isotopes (or zirconium after delayed proton emission); those with mass 99 or higher by ordinary beta decay to technetium. The most stable of the former are 93Mo, recently measured to have a half-life around 4800 years, and 90Mo at 5.56 hours. The most stable of the latter is the medically important 99Mo, half-life 65.932 hours, and whose decay leads to the chief isotope of technetium. By far the most stable isomer is 93m1Mo at 6.85 hours, decaying to its ground state.
== Nonclinical toxicology == Sitagliptin: Using male and female rats, a two-year carcinogenicity study was carried out with doses of 50, 150, and 500 mg/kg/day. The 500 mg/kg dose has exposure limits of 60 times what would be seen in the highest dose in humans. At this dose, liver adenoma/carcinoma was seen. Tumors were not seen from the smaller doses. Nomutagenic or clastogenic effects were seen from tests using several assays (CHO, rat, etc.). Fertility studies in rats showed no teratogenic effects. Simvastatin: No tumorigenic effect was seen in a 72-week carcinogenicity study using mice at the low dose levels. However, at the higher dose levels (eight and 16 times the human dose equivalent), liver carcinomas and adenomas, lung adenomas, and adenomas of the Harderian gland occurred. No mutagenic effects were seen in assays. Testicular atrophy was noted in dogs and rats at four and eight times the human exposure, respectively.
Sources: en.wikipedia.org
== Further reading == Nakagawa, Allen S., LIMS implementation and management, Cambridge: Royal Society of Chemistry, 1994 Liscouski, Joe, Laboratory and Scientific Computing a Strategic Approach, John Wiley & Sons, New York, 1995 Gibbon, Gerst, "A Brief History of LIMS", Laboratory Automation and Information Management 1996, 32(1), 1-5 Myers, J. D.; Fox-Dobbs, C.; Laird, J.; Le, Dai; Reich, D.; Curtz, T., "Electronic laboratory notebooks for collaborative research", In Proceedings of the 5th International Workshops on Enabling Technologies: Infrastructure for Collaborative Enterprises (WET ICE'96) (WET-ICE '96) IEEE Computer Society, Washington, DC, USA, 1996, 47-. Paszko, Christine; Pugsley, Carol, "Considerations in selecting a laboratory information management system (LIMS)", American Laboratory, 2000, 32(18), 38-42 Paszko, Christine; Turner, Elizabeth; Hinton, Mary D., Laboratory Information Management Systems, Revised & Expanded.
Eluxadoline, sold under the brand names Viberzi and Truberzi, is a medication taken by mouth for the treatment of diarrhea and abdominal pain in individuals with diarrhea-predominant irritable bowel syndrome (IBS-D). It was approved for use in the United States in 2015. The drug originated from Janssen Pharmaceutica and was developed by Actavis.
Leon Aarons is an Australian chemist who researches and teaches in the areas of pharmacodynamics and pharmacokinetics. He lives in the United Kingdom and from 1976 has been a professor of pharmacometrics at the University of Manchester. In the interest of promoting the effective development of drugs, the main focus of his work is optimizing pharmacological models, the design of clinical studies, and data analysis and interpretation in the field of population pharmacokinetics. From 1985 to 2010 Aarons was an editor emeritus of the Journal of Pharmacokinetics and Pharmacodynamics and is a former executive editor of the British Journal of Clinical Pharmacology.
Sources: en.wikipedia.org
Short-term storage is often at refrigerated temperatures, while longer storage may use freezing. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation. Container material and headspace can also affect stability.
Mass spectrometry is commonly used to confirm molecular mass and detect modifications. Reversed-phase high-performance liquid chromatography can assess purity and separate related impurities. These methods are complementary rather than interchangeable.
Turbidity can indicate aggregation, precipitation, or microbial contamination. It may also result from incomplete dissolution or undissolved excipients. The cause is not identifiable from appearance alone.
Most reconstituted peptide solutions are kept cold, often at 2–8 °C for short-term use. Longer storage may require freezing at -20 °C or below, depending on the peptide. Repeated freeze-thaw cycles can promote aggregation or degradation.